This 2011 pilot, randomized, placebo-controlled, double-blind study evaluated the efficacy of phosphatidylcholine (Lipostabil) injections for reducing prominent lower eyelid fat pads. Forty-five patients received 0.5 mL of Lipostabil in one lower eyelid and 0.5 mL of isotonic saline in the contralateral eyelid. Among the 23 patients who completed the study,
This 2006 open-label study assessed the efficacy and safety of phosphatidylcholine (PPT) injections for reducing infraorbital fat pads in 21 subjects. Each participant received 0.4 mL of PPT injected into the lower eyelid fat pads every 6 weeks. After two to three treatments, 74% of subjects exhibited significant cosmetic improvement,
This 2013 commentary by Diane Duncan critically evaluates the study by Reeds et al., which investigated the effects of phosphatidylcholine (PC) and deoxycholate (DC) injections on subcutaneous fat. Duncan highlights the study’s findings that PC-DC injections can reduce abdominal fat thickness without significant systemic metabolic changes. However, she raises concerns
This 2012 study investigated the effects of phosphatidylcholine (PC) and deoxycholate (DC) injections on human adipose tissue. Histological analysis revealed that the treatment induced fat cell necrosis rather than apoptosis. The findings suggest that the fat-reducing effects are due to nonspecific cell and tissue destruction, raising concerns about the safety
This 2009 study investigated the cytolytic effects of Lipostabil®, a phosphatidylcholine-based compound used in injection lipolysis, on various human cell types. In vitro experiments demonstrated that Lipostabil® induces rapid cell death in adipocytes, preadipocytes, vascular smooth muscle cells, skeletal myotubes, and renal epithelial cells. The cytolysis was not attributed to
This 2007 pilot study by Kopera et al. evaluated the efficacy of a phosphatidylcholine, deoxycholate, and ethanol (PPC/DC/E) formulation for reducing localized fat in the trochanteric (“saddlebag”) region. In a half-side controlled design, the right posterior trochanteric area of participants received three PPC/DC/E injections at weeks 0, 3, and 6,
This 2003 study by Rittes evaluated the efficacy of phosphatidylcholine injections for reducing localized fat deposits in 50 patients. Each patient received 5 mL (250 mg) of phosphatidylcholine per 80 cm² area using a 30G½ insulin needle. Pre- and post-treatment photographs were taken for analysis. Results showed a marked reduction
